Sermorelin vs CJC-1295

An FDA-approved growth-hormone-releasing hormone (GHRH) analogue that stimulates the pituitary to release natural GH. Staple of anti-aging clinics and the gateway GH secretagogue.

A synthetic GHRH analogue that stimulates pituitary growth hormone release. The short-acting form (no DAC) is typically paired with a ghrelin agonist like ipamorelin.

Sermorelin is the first 29 amino acids of endogenous GHRH — enough to bind the pituitary GHRH receptor and trigger physiological GH pulses. Unlike exogenous HGH, endogenous feedback loops remain intact.

CJC-1295 is a modified fragment of growth-hormone releasing hormone (residues 1–29) with four amino-acid substitutions that extend its half-life. The "no DAC" variant lacks the drug affinity complex tag and therefore has a shorter duration, producing physiological GH pulses.

200–500 mcg subcutaneous at bedtime

100–200 mcg, 1–3 times daily (research protocols)

~11–12 minutes

~30 minutes (no DAC); ~7 days (with DAC)

Subcutaneous

Subcutaneous

approved

research-only

Not yet listed

£22 · £11/mg via Peptides UK